# SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)

> **NCT00732810** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 97 (actual)

## Conditions studied

- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** SCH 727965
- **DRUG:** Capecitabine
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT00732810
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2015-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00732810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00732810, "SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00732810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*